CO5680438A2 - Uso de derivados de ciclotiocarbamato en tratamiento de condiciones relacionadas con hormonas - Google Patents

Uso de derivados de ciclotiocarbamato en tratamiento de condiciones relacionadas con hormonas

Info

Publication number
CO5680438A2
CO5680438A2 CO05004450A CO05004450A CO5680438A2 CO 5680438 A2 CO5680438 A2 CO 5680438A2 CO 05004450 A CO05004450 A CO 05004450A CO 05004450 A CO05004450 A CO 05004450A CO 5680438 A2 CO5680438 A2 CO 5680438A2
Authority
CO
Colombia
Prior art keywords
substituted
alkyl
group
aryl
carbon
Prior art date
Application number
CO05004450A
Other languages
English (en)
Inventor
Kern Jeffrey Curtis
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CO5680438A2 publication Critical patent/CO5680438A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1.- El uso del compuesto de la fórmula I o la fórmula II, o un tautómero del mismo, en la preparación de un medicamento para el uso en la inducción de la contracepción, dicho medicamento usado en combinación con al menos un modulador del receptor de estrógeno selectivo, caracterizado porque:la fórmula I tiene la estructura: en donde:R1 y R2 son sustituyentes independientes seleccionados del grupo que consiste de H, alquilo C1 a C6, alquilo C1 a C6 sustituido, alquenilo C2 a C6, alquenilo C2 a C6 sustituido, alquinilo C2 a C6, alquinilo C2 a C6 sustituido, cicloalquilo C3 a C8, cicloalquilo C3 a C8 sustituido, arilo, arilo sustituido, anillo heterocíclico basado en carbono que tiene en su esqueleto 1 a 3 heteroátomos, anillo heterocíclico basado en carbono sustituido que tiene en su esqueleto 1 a 3 heteroátomos, CORA, y NRBCORA;ó R1 y R2 están fusionados para formar un anillo seleccionado del grupo que consiste de a), b) y c), en donde dicho anillo es opcionalmente sustituido por 1 a 3 sustituyentes seleccionados del grupo que consiste de H y alquilo C1 a C3;a) un anillo espirocíclico saturado de 3 a 8 miembros basado en carbono;b) un anillo espirocíclico de 3 a 8 miembros basado en carbono que tiene uno o más dobles enlaces carbono carbono; y c) un anillo espirocíclico de 3 a 8 miembros que tiene en su esqueleto uno a tres heteroátomos seleccionados del grupo que consiste de O, S y N;RA es seleccionado del grupo que consiste de H, alquilo C1 a C3, alquilo C1 a C3 sustituido, arilo, arilo sustituido, alcoxilo C1 a C3, alcoxilo C1 a C3 sustituido, amino, aminoalquilo C1 a C3, y aminoalquilo C1 a C3 sustituido;RB es seleccionado del grupo que consiste de H, alquilo C1 a C3, y alquilo C1 a C3 sustituido;R3 es seleccionado del grupo que consiste de H, OH, NH2, alquilo C1 a C6, alquilo C1 a C6 sustituido, alquenilo C3 a C6, alquenilo C3 a C6 sustituido, alquinilo, alquinilo sustituido, y CORC;RC es seleccionado del grupo que consiste de H, alquilo C1 a C4, alquilo C1 a C4 sustituido, arilo, arilo sustituido, ...
CO05004450A 2002-06-25 2005-01-20 Uso de derivados de ciclotiocarbamato en tratamiento de condiciones relacionadas con hormonas CO5680438A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39187102P 2002-06-25 2002-06-25

Publications (1)

Publication Number Publication Date
CO5680438A2 true CO5680438A2 (es) 2006-09-29

Family

ID=30000766

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05004450A CO5680438A2 (es) 2002-06-25 2005-01-20 Uso de derivados de ciclotiocarbamato en tratamiento de condiciones relacionadas con hormonas

Country Status (19)

Country Link
US (1) US7192956B2 (es)
EP (1) EP1515725A4 (es)
JP (1) JP2005535624A (es)
KR (1) KR20050013247A (es)
CN (1) CN1662241A (es)
AR (1) AR040333A1 (es)
AU (1) AU2003247608A1 (es)
BR (1) BR0312024A (es)
CA (1) CA2489847A1 (es)
CO (1) CO5680438A2 (es)
CR (1) CR7611A (es)
EC (1) ECSP055576A (es)
IL (1) IL165396A0 (es)
MX (1) MXPA04012421A (es)
NO (1) NO20045216L (es)
RU (1) RU2005101638A (es)
TW (1) TW200404548A (es)
WO (1) WO2004000801A2 (es)
ZA (1) ZA200410411B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
TW200407124A (en) * 2002-06-25 2004-05-16 Wyeth Corp Use of thio-oxindole derivatives in treatment of hormone-related conditions
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
AU2005233648B2 (en) * 2004-04-08 2011-06-23 Wyeth Methods for minimizing thioamide impurities
ES2317223T3 (es) * 2004-04-08 2009-04-16 Wyeth Derivados de tioamida como moduladores del receptor de progesterona.
MXPA06012402A (es) * 2004-04-27 2007-01-17 Wyeth Corp Carbamato y tiocarbamato biarilos ciclicos que contienen cianopirrol y metodos para preparar los mismos.
CA2575737C (en) * 2004-08-13 2013-09-24 Wyeth Tanaproget derivatives, metabolites, and uses thereof
US7399766B2 (en) * 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
CN101027321A (zh) * 2004-08-20 2007-08-29 惠氏公司 孕酮受体结构
ATE460937T1 (de) * 2005-04-28 2010-04-15 Wyeth Corp Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung
EP1877059B8 (en) 2005-04-28 2010-05-19 Wyeth a Corporation of the State of Delaware Micronized tanaproget and compostions containing same
BRPI0610156A2 (pt) * 2005-04-28 2016-08-16 Wyeth Corp forma micronizada de um composto, forma purificada i do composto, kit, padrão de referência, e, método de preparaçao de uma composição farmacêutica.
AU2011226814B2 (en) * 2005-04-28 2013-06-13 Wyeth Llc Micronized tanaproget, compositions, and methods of preparing the same
AU2011203520B2 (en) * 2005-04-28 2012-06-14 Wyeth Micronized tanaproget and compostions containing same
DE602006007453D1 (de) * 2005-04-28 2009-08-06 Wyeth Corp Zusammensetzungen mit mikronisiertem tanaproget
CN101166736B (zh) * 2005-04-28 2013-02-06 惠氏公司 他那普戈特的多晶型ⅱ
CN101193639A (zh) * 2005-06-09 2008-06-04 惠氏公司 含有炔雌醇的tanaproget组合物
CA2672835A1 (en) * 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Processes for the preparation of (3r, 4r) -n- (4-chlorophenyl) -1- (2, 2-difluoroethyl) -n'- [2-fluoro-4- (2-oxo-1 (2h) -pyridinyl) phenyl] -3 , 4-pyrrolidinedicarboxamide
US20090170823A1 (en) * 2007-12-20 2009-07-02 Duramed Pharmaceuticals, Inc. Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
EP2475366A1 (en) * 2009-09-11 2012-07-18 Bayer Pharma Aktiengesellschaft Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
ES2627692T3 (es) 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Moduladores de receptores de estrógenos y usos de los mismos
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
US20170014174A1 (en) * 2015-07-17 2017-01-19 Candela Corporation Cryogenic Cylinder

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
WO1985000519A1 (en) 1983-07-29 1985-02-14 Duke University Method of treating androgen-related disorders
GB2310660A (en) 1996-03-01 1997-09-03 Merck & Co Inc Benzoxazinone oxytocin receptor antagonists
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6326392B1 (en) * 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
ES2258342T3 (es) 1998-10-23 2006-08-16 Aventis Pharma S.A. Preparaciones para aplicacion topica de sustancias que tienen efecto antiandrogenico.
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6258802B1 (en) * 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
WO2001030356A1 (fr) * 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
US20010034340A1 (en) * 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
GB0010683D0 (en) * 2000-05-03 2000-06-28 Univ Bristol Cancer therapy
FR2814074B1 (fr) * 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique

Also Published As

Publication number Publication date
EP1515725A4 (en) 2005-09-21
ZA200410411B (en) 2007-06-27
TW200404548A (en) 2004-04-01
AR040333A1 (es) 2005-03-30
US7192956B2 (en) 2007-03-20
AU2003247608A1 (en) 2004-01-06
WO2004000801A2 (en) 2003-12-31
JP2005535624A (ja) 2005-11-24
CA2489847A1 (en) 2003-12-31
BR0312024A (pt) 2005-03-22
IL165396A0 (en) 2006-01-15
CN1662241A (zh) 2005-08-31
WO2004000801A3 (en) 2004-03-25
ECSP055576A (es) 2005-04-18
US20040006060A1 (en) 2004-01-08
CR7611A (es) 2006-05-30
MXPA04012421A (es) 2005-04-19
NO20045216L (no) 2005-01-24
KR20050013247A (ko) 2005-02-03
RU2005101638A (ru) 2006-01-20
EP1515725A2 (en) 2005-03-23

Similar Documents

Publication Publication Date Title
CO5680438A2 (es) Uso de derivados de ciclotiocarbamato en tratamiento de condiciones relacionadas con hormonas
CO5680439A2 (es) Derivados de ciclotiocarbamato como moduladores de pr y su uso para el tratamiento de desordenes de la piel
BR0112856A (pt) Método para o tratamento dos distúrbios, composto ou um sal ou solvato deste, processo para a preparação dos mesmos, composição farmacêutico, método de tratamento e/ou profilaxia de um ou mais dos distúrbios, uso de um composto, e, método para o tratamento de diabetes, grande depressão, depressão manìaca, ansiedade, esquizofrenia e distúrbios do sono, em mamìferos humanos e não humanos
AR027406A1 (es) Moduladores de receptores canabinoides, sus procesos de preparacion y uso de los moduladores de receptores canabinoides para el tratamiento de enfermedadesrespiratorias y no respiratorias.
AR035774A1 (es) Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento
NZ511394A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AR019626A1 (es) Antagonistas receptores y5 de neuropeptidos.
AR035548A1 (es) Compuestos organicos
NI200700270A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR049398A1 (es) Derivados de sulfamato y sulfamida; una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento util para el tratamiento de la epilepsia y trastornos relacionados.
ECSP056016A (es) Nuevos derivados de 2-piridinacarboxamida
ECSP045483A (es) Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso
CO5590915A2 (es) Derivados de piperidina como antagonistas nk1 ( receptor del neuropeptido neuroquinina-1) con actividad antagonista superior en tratamientos de trastornos fisiologicos y disminucion de efectos colaterales
CO5590957A2 (es) Amino-1,3,5-triazinas sustituidas en n con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas y su uso como herbicidas y reguladores del crecimiento de las plantas
BRPI0609711B8 (pt) uso de uma solução aquosa com potencial redutivo oxidativo (orp)
CL2009000323A1 (es) Compuestos derivados de heterociclos no condensados sustituidos, inhibidores de la funcion de la proteina ns5a; composicion farmaceutica que los comprende; y su uso para tratar la infeccion del virus de la hepatitis c.
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
ES2195785B1 (es) Nuevos derivados de piridazin-3(2h)-ona.
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
BRPI0814382A2 (pt) Composto, uso do composto, e, composição farmacêutica
TW200637559A (en) 3-propenylcefem derivative
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
AR042706A1 (es) Compuestos (2-carboxamido)(3-amino) tiofenos y su uso para el tratamiento del cancer
BRPI0417948A (pt) derivados de quinuclidina substituìda por bicicloheterociclo fundido
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso

Legal Events

Date Code Title Description
FA Application withdrawn